Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • lecanemab

    - PMLiVE

    Eisai submits new drug application for subcutaneous Leqembi in Japan

    LEQEMBI is a treatment for early Alzheimer’s disease

    - PMLiVE

    Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment

    The MHRA approval for IV dosing comes following positive results from the global phase 3 trial

    - PMLiVE

    Lilly and WHO Foundation partner to support global dementia action plan

    The partnership will provide financial support and strengthen early detection and intervention efforts

    - PMLiVE

    Biogen expands portfolio in deal with Alcyone Therapeutics

    The agreement gives Biogen full rights to a potential therapy for patients with neurological disorders

    - PMLiVE

    Eli Lilly’s Alzheimer’s drug Kisunla shows growing benefit in long-term study

    More than seven million people in the US are affected by the neurodegenerative disease

    Biogen Idec building

    Biogen/Eisai’s Alzheimer’s drug Leqembi shows continued benefit over four years

    An estimated 13 million people in the US will be living with Alzheimer’s disease by 2050

    Biogen Idec building

    Biogen’s Qalsody granted MHRA approval to treat rare form of motor neurone disease

    Mutations in the SOD1 gene are responsible for approximately 2% of all cases of the disease

    - PMLiVE

    Roche shares promising data from Alzheimer’s disease development portfolio

    The company is planning to initiate phase 3 studies of trontinemab in early AD this year

    Biogen Idec building

    Biogen to boost US manufacturing footprint with $2bn North Carolina investment

    The commitment is aimed at advancing the company's late-stage clinical pipeline

    Biogen Idec building

    Biogen initiates phase 3 study of felzartamab in kidney disease patients

    Approximately 36,000 people in the US are affected by primary membranous nephropathy

    - PMLiVE

    UKDRI researchers to evaluate new blood test for neurodegenerative disease diagnosis

    It is hoped that the test could be available for widespread UK use in the coming years

    Biogen Idec building

    Biogen and City Therapeutics to develop RNAi therapies in deal worth over $1bn

    The partners will focus on a target that mediates key central nervous system diseases

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links